Pavmed Inc. · NASDAQ:PAVM
Pavmed — Investor Presentation (March 2018)
26 slides from Pavmed's investor presentation, Mar 21, 2018
Slide 1: PAVmed Inc. Investor Presentation
¥&« PAVmed INNOVATING AT THE SPEED OF LIFE™ — oS AH} LISHAN AKLOG MD Chairman & CEO PAVmed Inc (Nasdaq: PAVM) March 20, 2018
Slide 2: Disclaimers
Disclaimers % This presentation contains certain forward-looking statements that involve risks and uncertainties. = Actual results and events may differ significantly from results and events discussed in forward-looking statements. + Factors that might cause or contribute to such differences include
Slide 3: Highly Differentiated, Multi-Product Medical Device Company
¥« PAVmed INNOVA T THE SPEED OF LIFE HIGHLY DIFFERENTIATED, MULTI-PRODUCT MEDICAL DEVICE COMPANY ¥ High-margin single-use interventional or acute care products X Broad spectrum of clinical conditions and specialty call points
Slide 4: Strong Track Record of Innovation and Milestones
Strong Track Record Speed to Market Two Near-term of Innovation and Milestones Value Creation Total Addressable Market over $3B Capital Efficiency Multiple Pathways to Commercialization
Slide 5: Key Recent Developments
Key Recent Developments % Steady progress towards major milestones for the lead products CARPX = Filed FDA 510(k) pre-market notification submission = Received encouraging initial FDA feedback including request for additional non- clinical support PORTIO. = Filed FDA de novo pre-submission package =
Slide 6: Management Team
Management Team SK PAVmed LISHAN AKLOG MD CHatRMAN & CEO MICHAEL GLENNON Vice CHaiRuan BRIAN DEGUZMAN DENNIS MCGRATH Execus Cuer OFFICER VANCIAL Harvar> = /\ Kl 2 Mount Sinai O92 em University of New Hampshire GUIDANT STORZ stryker weal sostoy GG Tava Oi o@ Tufts = Se open OU UNIVERSITY ARTHUR ANDER
Slide 7: Capital Structure
Capital Structure PAVmed, Inc (Nasda AVM, PAVMW) Exercise/ Common Stock Insider Conversion Price Equivalents Outstanding Ownership (Weighted Avg.) (Treasury) Common Stock 17,235,397 4% ad 17,235,397 Preferred Stock 606,926 sa ol 702,750 Warrants 12,807,978 66% $4.47 1,465,423 Options 3,060,032 ioe $
Slide 8: Business Model
Business Model MULTI-PRODUCT PIPELINE RISK MITIGATION ¥ Non-binary success COMMERCIAL OPPORTUNITY ATTRACTIVE MARKET v Unmet clinical need KEY BUSINESS PROCESSES CAPITAL EFFICIENCY & SPEED TO MARKET ¥ Outsourced best-in- class process experts ECONOMIES OF SCALE CORPORATE FLEXIBILITY ¥ Dynamic resourc
Slide 9: Lead Products
Lead Products PRODU MARKET REGULA OPPORTUNITY PATH CARPX Percutaneous Device to treat >$1B 510(k) Carpal Tunnel Syndrome PORTIO /mplantable Intraosseous >$750M de novo Vascular Access Device Antibiotic-Eluting ~$300M 510(k) Ng DISAPPEAR Resorbable Ear Tubes SR pavmed Oe a set
Slide 10: Multiple Pathways to Commercialization
Multiple Pathways to Commercialization Tailored to Maximize Value Creation TARGETED INITIAL COMMERCIALIZATIO! + Key Opinion Leaders + Independent Distributors CORPORATE CORPORATE FULL SELF ACQUIRER PARTNER COMMERCIALIZATION + Asset sale to strategic + Sales & distribution + Hybrid sales channel + No
Slide 11: CarpX
= GO itr CarpX Minimally Invasive Device to Treat Carpal Tunnel Syndrome
Slide 12: Carpal Tunnel Syndrome
Carpal Tunnel Syndrome CLINICAL OVERVIEW % Incidence = Over 600,000 U.S. procedures annually = Up to 1.5 million with symptoms who “suffer in silence” 3 Mechanism = Inflammation and scarring of transverse carpal ligament = Entrapment of the median nerve = hand pain, numbness and weakness
Slide 13: Carpal Tunnel Syndrome: Market Opportunity
Carpal Tunnel Syndrome MARKET OPPORTUNITY % 600,000 current surgeries x $1,500 minimum ASP = ~$1 Billion % Additional 1.5M “silent sufferers” who choose to defer surgery UNMET CLINICAL NEED — CURRENT LIMITATIONS TRADITIONAL CARPAL TUNNEL ENDOSCOPIC SURGERY SURGERY IS INVASIVE + Up to 2 inch incision
Slide 14: CarpX — Minimally Invasive CTS Device Key Features
CarpX — Minimally Invasive CTS Device 3 Key Features * Single-use device * Connects to standard electrosurgical generator * Balloon creates anatomic separation ¥ Protects nerve and tendons by pushing them away from ligament * Balloon tensions ligament ¥ Facilitates cutting of ligament by stretching
Slide 15: CarpX in Action
CarpX in Action Rion relieved, no ransverse carpal ligament cut Balloon inflated (sideview) SK PAVmed
Slide 16: CarpX — Advantages
CarpX — Advantages LESS INVASIVE MORE COST EFFECTIVE Option to perform the procedure + Shift from OR to interventional lab truly percutaneously + Shorten procedural times Less pain, scarring + Shorten time out of work - Accelerate time to full recovery Anticipate 1-2 weeks vs often >6 months FEWER C
Slide 17: CarpX — Current Status
CarpX — Current Status ‘ Cadaver Testing * Extensive testing showed clean, consistent cutting of ligament % FDA 510(k) Submission = Filed FDA 510(k) pre-market notification submission v_ Existing carpal tunnel release system as predicate = Received encouraging initial FDA feedback = Working with FDA
Slide 18: PortIO
PortlO /mplantable Intraosseous Vascular Access Devices
Slide 19: Vascular Access Devices
Vascular Access Devices Used to deliver medications, fluids, nutrition and other substances | ER | INPATIENT <24 Hours | <7-10 days | <6 weeks <1 year | Peripheral IV Central Venous Tunneled Central - Catheter (CVC) Venous Catheter te 2 Awe = Intraosseous Peripherally Inserted Central Implantable Po
Slide 20: Vascular Access Devices: Unmet Clinical Need
Vascular Access Devices UNMET CLINICAL NEED — CURRENT DEVICE LIMITATIONS Limitations driven by intravascular component - Up to 35% + Up to 10% 4 + Clot-busting medications or + 50% life-threatening a repeat procedure bloodstream infections + >10% of patients + Surgical insertion & + Pacemaker/Defibr
Slide 21: Intraosseous Vascular Access
Intraosseous Vascular Access %& Infusion directly into the Bone Marrow Cavity %& Decades of experience using temporary needle access * Trauma, esp. military * Pediatric emergencies * Bioequivalent to intravenous route SK PAVmed
Slide 22: PortIO — Implantable Intraosseous Port
PortlO — Implantable Intraosseous Port % Key Features = Implanted into bone Y Tip positioned in bone marrow v No Intravascular Component = Functionally identical to traditional implantable port v Resides under the skin Implantable Port a v Patient can bathe/swim v Standard Huber access needle (Zz Ho
Slide 23: PortIO — Market Opportunity
PortlO — Market Opportunity Duration Duration Duration <24 Hours <T7-10 days <6 weeks <1 year Market Size Market Size Market Size ~$150M (Current IO pts) ~$200M (Poor vein pts) ~$500M Advantages Advantages Advantages + Near limitless access sites + Near limitless access sites + Near limitless access
Slide 24: PortIO — Current Status FDA de novo Pathway
PortlO — Current Status 3 FDA de novo Pathway = Filed FDA de novo pre-submission package = Initial indication targeting inpatient use for up to 7 days ¥ Once cleared can then serve as own predicate for 510(k) submissions for expanded 6-week/outpatient and 6-month/home use indications = Productive in
Slide 25: Growth Strategy
Growth Strategy % Advance lead products to commercialization = CarpX — Target 510(k) clearance by end of Q2-2018 = PortlO - Complete de novo animal study target IDE submission by end of Q2-2018 = DisappEAR — Target Q3 2018 FDA 510(k) submission %& Pursue strategic initiatives to enhance shareholder
Slide 26: Strong Track Record of Innovation and Milestones
Strong Track Record Speed to Market Two Near-term of Innovation and Milestones Value Creation Total Addressable Market over $3B Capital Efficiency Multiple Pathways to Commercialization